Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merck Kgaa (OP: MKGAF ) 188.00 +4.12 (+2.24%) Streaming Delayed Price Updated: 3:15 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 100 Open 186.45 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 183.88 Today's Range 186.30 - 188.00 52wk Range 143.46 - 200.56 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED August 17, 2024 Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... Via Talk Markets Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis December 06, 2023 Merck KGaA (OTC: MKGAF) (OTC: Via Benzinga Performance YTD +21.68% +21.68% 1 Month +4.00% +4.00% 3 Month +2.73% +2.73% 6 Month +6.82% +6.82% 1 Year +5.32% +5.32% More News Read More Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion November 04, 2023 Via Talk Markets Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors September 26, 2023 Via Benzinga Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 August 03, 2023 Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 Via Benzinga Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation June 20, 2023 Via Benzinga Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows May 17, 2023 Via Benzinga Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions April 18, 2023 Via Benzinga FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study April 12, 2023 Via Benzinga Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer March 27, 2023 Via Benzinga Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval March 23, 2023 Via Benzinga PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment January 03, 2023 Via Benzinga Mersana Inks Cancer Therapy Development Deal With Merck Germany December 23, 2022 Via Benzinga GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact September 30, 2021 Via Benzinga Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study September 21, 2021 Via Benzinga Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial August 24, 2021 Via Benzinga Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck June 01, 2021 Via Benzinga Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors June 01, 2021 Via Benzinga Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share May 14, 2021 Via Benzinga Topics Initial Public Offering Exposures Securities Market UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer May 10, 2021 Via Benzinga Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company April 20, 2021 Via Benzinga Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio April 07, 2021 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
